International Vaccine Access Center
Featured
Tracking Measles Cases in the U.S.
Measles outbreaks have been reported in multiple states, highlighting the importance of measles vaccination and rapid detection and reporting of suspected and confirmed measles cases.
Latest WUENIC Data Shows Plateau in Global Vaccination
2024 WUENIC data show that while there has been some progress made in reaching every child with life-saving vaccines, we still have a lot of ground to cover to meet ambitious IA2030 targets in the next five years.
U.S. Measles Cases Hit Highest Level in Decades
The United States surpassed a milestone in reported measles cases, with 2025 now having the most cases since the disease was declared eliminated in the U.S. in 2000.
Accelerating global access to life-saving vaccines.
We apply rigorous science to build knowledge and support for the value of vaccines.
IVAC's Work
The International Vaccine Access Center accelerates equitable and sustainable access to vaccines in low- and middle-income countries by generating, synthesizing, and using evidence to inform decision making and action.
Where We Work
IVAC works with governments and major research institutions in 38 countries. Learn more about us.
What We Do: Project Highlights
Vaccine Information and Epidemiology Window (VIEW-HUB)
VIEW-hub is IVAC’s publicly accessible interactive platform to visualize real-time information on vaccine use, product type, coverage levels, impact assessments, and disease burden estimates. It can be utilized to track progress and strategize ways to accelerate and optimize vaccine implementation.
READ MORE>
Vaccine Economics Research for Sustainability & Equity (VERSE)
VERSE will compute the economic benefits and return-on-investment of vaccines, create a standardized model for assessing, tracking, and targeting vaccine coverage inequity at the country level and for monetizing the economic losses due to inequity, and more.
READ MORE >
Stay Connected
Sign up for our monthly newsletter to receive the latest updates on immunization-related science, policy, and access from the International Vaccine Access Center at the Johns ÎÚÑ»´«Ã½.